Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905694 · ClinicalTrials.gov registry record · Phase 3
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
A Phase 3 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT03905694 is a Phase 3 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT03905694, a Phase 3 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
Interventions
- DRUG Lumasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2024-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03905694
The ClinicalTrials.gov registry entry for NCT03905694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumasiran is the first listed.
NCT03905694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03905694 about?
NCT03905694 is a clinical study titled "A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1". The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
What is the current status of trial NCT03905694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2019-04-22. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT03905694?
The interventions under investigation include: Lumasiran (DRUG).
Who is sponsoring clinical trial NCT03905694?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.